Retinal hemorrhages following fingolimod treatment for multiple sclerosis; a case report. Issue 1 (December 2015)

• Record Type: Journal Article
• Authors: Ueda, Naoko; Saida, Kyoko
• Is Part Of: BMC ophthalmology. Volume 15:Issue 1(2015)
• Page Start: 1
• Page End: 5
• Publication Date: 2015-12
• Subjects: Retinal hemorrhages -- Fingolimod -- Relapsing-remitting multiple sclerosis -- Side effect -- Macular edema; Ophthalmology -- Periodicals; 617.7005
• DOI: 10.1186/s12886-015-0125-9
• Languages: English
• ISSNs: 1471-2415

Abstract

Abstract Background Fingolimod is the first oral agent used for treatment of relapsing-remitting multiple sclerosis. Macular edema, but not retinal hemorrhage, is a well-known adverse effect of fingolimod treatment. To the best of our knowledge, this is the first case report of extensive retinal hemorrhages following fingolimod treatment. Case presentation A 31-year-old male with relapsing-remitting multiple sclerosis developed macular edema and retinal hemorrhages in his left eye, 1 month after starting fingolimod treatment; treatment was then discontinued. The hemorrhages were flame-shaped, and were extensive along retinal arteries and veins. The hemorrhages started to decrease at 4 weeks and disappeared completely at 24 weeks after cessation of fingolimod treatment. Conclusions Occurrence of retinal hemorrhage warrants careful follow-up for multiple sclerosis patients treated with fingolimod.